AIDD: A New Imaging‑Based Approach to Dementia Differentiation
GAINESVILLE, Fla. — Neuropacs™ Corp., a leader in AI‑powered neurodiagnostics, today announced the publication of a major new study led by David Vaillancourt, PhD, the company’s Co‑Founder and Chief Scientific Officer. The research published in Neurology Open Access introduces Automated Imaging Differentiation for Dementia (AIDD), a machine‑learning approach that combines diffusion free‑water imaging with support vector modeling to distinguish Alzheimer’s disease dementia (ADD) from dementia with Lewy bodies (DLB) with exceptionally high accuracy. https://www.neurology.org/doi/10.1212/WN9.0000000000000093
Early and accurate differentiation of ADD and DLB is essential because 1) DLB patients are highly sensitive to antipsychotics, 2) Treatment pathways differ substantially, 3) Misdiagnosis rates remain high under current standards of care and 4) Disease‑specific stratification is a major barrier in drug development trials. The study analyzed 519 diffusion MRI scans from the AD Neuroimaging Initiative (ADNI), the National Alzheimer’s Coordinating Center (NACC), and the Parkinson’s Disease Biomarker Program (PDBP), including individuals with ADD, DLB, and age‑matched controls. AIDD achieved high AUC values in differentiating ADD from DLB in both training and testing datasets, and predictions were pathologically confirmed in a subset of patients with postmortem data. “This work demonstrates the power of diffusion MRI and machine learning to address one of the most persistent diagnostic challenges in dementia,” said Dr. Vaillancourt, senior author of the study. “Distinguishing Alzheimer’s disease from Lewy body dementia is critical for patient safety, treatment selection, and clinical trial stratification. AIDD shows that advanced imaging analytics can provide the clarity clinicians have long needed.”
AIDD builds on the same scientific foundation as Automated Imaging Differentiation for Parkinsonism (AIDP), which the FDA recently granted de novo classification for parkinsonism. https://sharp-northcutt.74-208-86-71.plesk.page/news/fda-grants-de-novo-classification-to-neuropacs-a-first-in-class-ai-based-mri-diagnostic-aid-for-parkinsonian-syndromes/.
Together, these technologies reflect the company’s commitment to delivering objective, imaging‑based biomarkers that improve diagnostic accuracy and accelerate therapeutic development. “This work continues to push the boundaries of what’s possible in neuroimaging,” said Dr. Martin Handfield, President & CEO of Neuropacs. “This publication reinforces the scientific foundation behind Neuropacs’ platform and highlights the transformative potential of diffusion MRI analytics in neurodegenerative disease.”
About Neuropacs™ Corp.
Neuropacs™ Corp. is an AI-enabled imaging company focused on developing software tools to support the evaluation of neurodegenerative diseases. Automated Imaging Diagnostics LLC, is a wholly owned subsidiary of Neuropacs Corp. Its platform leverages advanced imaging analytics to provide insights for clinical and research applications. https://sharp-northcutt.74-208-86-71.plesk.page/
About neuropacs™
neuropacs™ is a prescription device that analyzes patient-specific data to aid in the diagnosis of Parkinsonian syndromes. The test requires a single, non-invasive, and radiotracer-free diffusion MRI scan, which can be acquired using standard diffusion MRI sequences available on 3 Tesla clinical MRI systems from Siemens, GE Healthcare, and Philips. The brain scan is analyzed using a rigorously validated free-water imaging model and machine learning algorithm. The device provides a classification report based on degenerative brain patterns of multiple system atrophy Parkinsonian variant (MSAp) and progressive supranuclear palsy (PSP) to help neuroradiologists and/or neurologists in differentiating these diseases from Parkinson’s disease (PD). Important Safety Information: The neuropacs™ system is intended to provide supplemental information and is not a standalone diagnostic device. Results should be interpreted in conjunction with clinical evaluation and other diagnostic testing. This device does not rule out other potential causes of Parkinsonism symptoms or signs and is intended to be used after all other potential causes of Parkinsonism symptoms (such as dementia with Lewy bodies, vascular Parkinsonism, drug-induced Parkinsonism, and corticobasal degeneration/syndrome) have been ruled out by trained clinicians on the basis of clinical, neurological, and other laboratory tests. Patient management decisions should not be based solely on neuropacs™ output.
Forward-Looking Statements
This communication includes express and implied “forward-looking statements.” Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. By their nature, these statements are subject to numerous risks and uncertainties, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law.
Media Contact: Martin Handfield, President & CEO, martin@neuropacs.com